4 July 2023: Premature infants in England can now receive drug treatment as a routine measure on the National Health Service (NHS), aimed at preventing blindness. This marks the first instance where such treatment is made available for premature babies within the NHS in England. Normally, infants who have Retinopathy
Bioinformatics
Biomedical engineering has emerged as a dynamic field at the intersection of healthcare and technology, offering a multitude of groundbreaking discoveries and innovations that have the potential to revolutionise healthcare. From novel medical devices and implants to cutting-edge diagnostic tools and regenerative therapies, biomedical engineering is paving the way for
London, 26 June 2023: Leading global pharmaceutical company GSK plc has made an announcement stating that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has provided a favourable opinion recommending the authorization of daprodustat. The recommendation is specifically for the treatment of symptomatic anaemia linked to
June 15, 2023: Scientists have created an insulin derived from plants, specifically lettuce, which is claimed to be a more affordable and secure substitute for regular hormone injections. A recent study led by Henry Daniell from Penn's School of Dental Medicine, published in the journal Biomaterials, highlights the potential of
London, June 15, 2023: The Health Minister of Saudi Arabia, Fahad Al-Jalajel and the Secretary of State for Health and Social Care in the UK, Steve Barcly have officially entered into a Memorandum of Cooperation (MoC) between their respective ministries, solidifying a formal agreement for joint efforts to strengthen collaboration
12 June 2023: Syncona Ltd has introduced its third gene therapy company Beacon Therapeutics Holdings Ltd. Beacon Therapeutics will bring together two preclinical ophthalmologic programs owned by Syncona with Applied Genetic Technologies Corp's (AGTC's) advanced X-linked retinitis pigmentosa (XLRP) program. Syncona has allocated £75 million to Beacon, which includes the
5 June 2023: RNA vaccine developer VaxEquity, in partnership with the Centre for Process Innovation (CPI), has successfully obtained a £700k grant from Innovate UK, an innovation agency based in the UK. This substantial funding will support a joint initiative aimed at progressing the manufacturing methods for RNA vaccines and
June 8, 2023: South Korea-based Samsung Biologics has secured a lucrative contract worth $411 million from pharmaceutical powerhouse Pfizer to produce biosimilars for it. As part of this agreement, Samsung will provide increased manufacturing capabilities to accommodate the production of a diverse range of biosimilars, including those related to oncology,
01 June 2023: A novel intracellular drug delivery centre is set to be established in the United Kingdom with the aim of providing extensive support for the advancement of ribonucleic acid (RNA) vaccines and therapeutics, as well as facilitating the progress of innovative drug delivery technologies. The UK intracellular drug
31 May, 2023: 3M, a company known for its expertise in industrial equipment manufacturing, intends to allocate £120 million to enhance its capacities in order to provide greater assistance to the rapidly expanding field of biotech manufacturing. The investment will involve enhancing facilities and equipment, along with the establishment of
In the vast realm of healthcare, technology has emerged as a driving force, catalysing the greatest breakthroughs and transforming the way we prevent, diagnose, and treat diseases. With each passing year, innovations in medical technology continue to push the boundaries of what was once considered unimaginable. From artificial intelligence to
25 May 2023: Jeremy Hunt, Chancellor of the Exchequer (Chief finance minister) has revealed the UK Government's plan to allocate a £650 million fund, aimed at propelling the growth and progress of the country's life sciences industry. The package has been portrayed as a substantial reserve of resources intended to